Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | SPR | P35270 | 2/20 | 0.49 |
| ▸ | CPT1A | P50416 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711879 | 0.90 | FAAH (0.59) | FAAHL3MBTL1HSD11B1HPGDSSPR | |
| SCHEMBL2358755 | 0.89 | HPGDS (0.66) | FAAHL3MBTL1HPGDSSPRCPT1A | |
| SCHEMBL25168713 | 0.88 | FAAH (0.51) | FAAHL3MBTL1HSD11B1SPRTRPV1 | |
| SCHEMBL3766121 | 0.88 | TRPV1 (0.53) | FAAHL3MBTL1HSD11B1TRPV1ALDH1A1 | |
| SCHEMBL3774063 | 0.87 | ALDH1A1 (0.49) | FAAHHPGDSTRPV1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18701751 | 0.86 | FAAH (0.56) | FAAHL3MBTL1HSD11B1HPGDSSPR | |
| SCHEMBL25167080 | 0.84 | NPC1 (0.55) | FAAHALDH1A1SMN1; SMN2 | |
| SCHEMBL3770630 | 0.84 | NPC1 (0.52) | FAAHL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1653297 | 0.83 | USP30 (0.59) | FAAHHPGDS | |
| SCHEMBL25168799 | 0.81 | FAAH (0.49) | FAAHHPGDSCPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308869-B1 | AZOLE COMPOUND | ASTELLAS PHARMA INC (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | FAAH 1/4885L3MBTL1 2773/4885HSD11B1 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.